Allyl-benzyl-dimethyl-ammoniumhydroxid | 22100-10-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Allyl-benzyl-dimethyl-ammoniumhydroxid
• 英文别名: N-Allyl-N-benzyl-N,N-dimethyl-ammoniumbromid；Allylbenzyl-dimethylammonium bromide；benzyl-dimethyl-prop-2-enylazanium;bromide
• CAS: 22100-10-3
• 化学式: Br*C₁₂H₁₈N
• 分子量: 256.186
• InChiKey: KWZBGJKXZXQXKB-UHFFFAOYSA-M

物化性质

• 熔点：
  98-100 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.55
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2923900090

反应信息

• 作为反应物：
  描述：

  Allyl-benzyl-dimethyl-ammoniumhydroxid 在 镍 氨 、 sodium amide 作用下， 以 乙醇 为溶剂， 生成 1-甲基-2-丙基
  参考文献：
  名称：

  Sommelet-Hauser Rearrangement of Allylbenzyldimethylammonium Bromide and Cyclopropylcarbinylbenzyldimethylammonium Bromide. Evidence for Carbanion Stabilization by the Cyclopropane Ring

  摘要：

  DOI：

  10.1021/ja00884a015
• 作为产物：
  描述：

  N,N-二甲基苄胺 、 3-溴丙烯 反应 2.0h， 以30%的产率得到Allyl-benzyl-dimethyl-ammoniumhydroxid
  参考文献：
  名称：

  季铵盐亲核取代组分交换的动态共价化学

  摘要：

  季铵阳离子的动态共价库（DCL中）通过可逆亲核取代（S设置Ñ 2'和S Ñ 2）铵盐和叔胺的交换反应。反应在60°C下进行，以生成季铵化合物和叔胺的热力学和动力学控制混合物，并通过使用碘化物作为亲核催化剂来加速反应。微波辐射用于辅助吡啶鎓盐和吡啶衍生物之间的交换反应。最后，进行了产生动态离子液体的实验。这项研究的结果为将动态组合化学扩展到亲核取代反应铺平了道路。

  DOI：

  10.1002/asia.201500604

文献信息

• FLUORESCENCE DETECTION OF POISON OAK OIL
  申请人：The Regents of the University of California

  公开号：US20130121924A1

  公开（公告）日：2013-05-16

  The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, and cashew nut.

  本公开的发明提供了用于合成所述组合物的方法，以及使用所述组合物的方法，其中这些组合物和方法可用于结合和/或使毒橡树油（如漆酚）失活。这些组合物和方法可用于治疗和/或减轻对毒橡树、毒藤、毒漆树、芒果、漆树和腰果中发现的天然化合物的炎症反应和/或过敏反应。
• PROCESS FOR THE PRODUCTION OF BRANCHED ALKYLBENZENES THAT USES A RENEWABLE CARBON SOURCE
  申请人：SANCHEZ Eric

  公开号：US20110275871A1

  公开（公告）日：2011-11-10

  A process for the production of alkylbenzenes in the presence of an aromatic feedstock and an olefinic stream produced from an ethanol feedstock, itself produced from a renewable source obtained from biomass, is described, with said process comprising at least: a) A stage for purification of said ethanol feedstock, b) A stage for dehydration of said purified ethanol feedstock, obtained from said stage a), into an effluent that is for the most part ethylene, c) At least one stage for separation of the water that is present in said effluent that is for the most part ethylene obtained from said stage b), d) A first stage for oligomerization of said effluent that is for the most part ethylene in the presence of at least one catalyst that comprises at least one element of group VIII, e) A second stage for oligomerization of at least some of the effluent that is obtained from said stage d) in the presence of at least one amorphous catalyst or at least one zeolitic catalyst, f) A stage for fractionation of the effluent that is obtained from said oligomerization stage e) in such a way as to recover at least one olefin-enriched olefinic stream that has a number of carbon atoms that is greater than or equal to 9, g) An alkylation stage of said olefinic stream that is obtained from said stage f) by at least one aromatic feedstock.

  描述了一种在芳烃原料和从生物质获得的可再生来源生产的乙醇原料产生的烯烃流的存在下生产烷基苯的方法，该方法至少包括：a）用于纯化所述乙醇原料的纯化阶段，b）用于将从阶段a）获得的纯化乙醇原料脱水为主要为乙烯的流出物的脱水阶段，c）至少一个用于分离主要为乙烯的流出物中存在的水的阶段，该流出物是从阶段b）获得的，d）在至少包括第VIII族元素的至少一个催化剂的存在下，在主要为乙烯的流出物的寡聚化的第一阶段，e）在至少一个非晶催化剂或至少一个沸石催化剂的存在下，在从阶段d）获得的至少一部分流出物的寡聚化的第二阶段，f）用以分馏从寡聚化阶段e）获得的流出物的阶段，以便回收至少一个碳原子数大于或等于9的烯烃富集的烯烃流，g）通过至少一种芳烃原料对从阶段f）获得的烯烃流进行烷基化阶段。
• COMPOSITIONS COMPRISING LIPOXYGENASE INHIBITORS AND CYCLODEXTRIN
  申请人：Kipp E. James

  公开号：US20070111965A1

  公开（公告）日：2007-05-17

  The present invention is directed to formulations of inclusion complexes of lipoxygenase inhibitors and cyclodextrins having a therapeutically effective concentration of the lipoxygenase inhibitor, methods of making the same and methods of treating disease states using the same. Forming cyclodextrin complexes permits the enhancement of the aqueous solubility of lipoxygenase inhibitors which allows higher concentrations of the lipoxygenase in solution. Aqueous formulations of lipoxygenase inhibitors-cyclodextrin complexes are suitable for parenteral or oral administration for treating and/or preventing inflammatory disease states. The aqueous formulations can be lyophilized to prolong storage stability, assist in oral administration and/or provide for convenient and economical packaging.

  本发明涉及含脂氧化酶抑制剂和环糊精的包含物复合物的配方，具有治疗有效浓度的脂氧化酶抑制剂，制备方法以及使用它们治疗疾病状态的方法。形成环糊精复合物可以增强脂氧化酶抑制剂的水溶性，从而允许在溶液中获得更高浓度的脂氧化酶。脂氧化酶抑制剂-环糊精复合物的水溶性配方适用于静脉或口服给药，用于治疗和/或预防炎症性疾病状态。水溶性配方可以冻干以延长储存稳定性，帮助口服给药和/或提供方便和经济的包装。
• Ionic liquids with a theophyllinate anion
  作者：Bartosz Markiewicz、Agata Sznajdrowska、Łukasz Chrzanowski、Łukasz Ławniczak、Agnieszka Zgoła-Grześkowiak、Krzysztof Kubiak、Jan Nawrot、Juliusz Pernak

  DOI：10.1039/c4nj00463a

  日期：——

  A novel group of theophylline-based ionic liquids displayed efficient antifeedant, fungicidal and bactericidal activities, proving to be promising for potential applications.

  一种新型的以茶碱为基础的离子液体表现出高效的抗喂食、杀菌和杀菌活性，证明其具有潜在的应用前景。
• COMPOSITIONS OF LIPOXYGENASE INHIBITORS
  申请人：Kipp E. James

  公开号：US20070134341A1

  公开（公告）日：2007-06-14

  Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.

  提供了包含脂氧合酶抑制剂化合物颗粒的制药组合物，其有效平均尺寸从大约10纳米到大约50微米。更具体地，提供了有效平均尺寸从大约50纳米到大约5微米的5-脂氧合酶抑制剂化合物颗粒的制药组合物。这些制药组合物以水悬浮液的形式存在，其中5-脂氧合酶抑制剂化合物的颗粒浓度为大约5到200毫克/毫升。此外，还提供了制备这种制药组合物的方法。具体来说，揭示了使用至少一种表面活性剂进行微相沉淀和直接均质化制备制药组合物的方法。